HK Stock Market Move | KEYMED BIO-B (02162) rose more than 6% in the afternoon; Kangyueda's indication for adolescent atopic dermatitis approved for marketing

KEYMED BIO-B (02162) rose more than 6% in the afternoon, up 4.45% as of press time at HK$85.4, with a turnover of HK$187 million. On the news front, according to Keymed Biosciences' official WeChat account recently, the company announced that the adolescent moderate-to-severe atopic dermatitis indication of its self-developed core product Kangyueda (stapokibart) has been approved for marketing by the National Medical Products Administration. This is the fourth indication approved for the product, further expanding its dermatology indication from adults to adolescent patients aged 12 and above. Chen Bo, Chairman and Chief Executive Officer of Keymed Biosciences, said that the approval of the adolescent atopic dermatitis indication for Kangyueda is another important milestone for Kangyueda in the dermatology field following adult moderate-to-severe atopic dermatitis, filling the gap in domestic biologic treatment for adolescent moderate-to-severe atopic dermatitis in China and bringing a new targeted biologic treatment option to adolescent patients with moderate-to-severe atopic dermatitis in China.